Take the overall health and condition of the patient into account for decision making of toxicity management. High-risk patients (e.g. high tumor burden or comorbidities) may require earlier intervention. Toxicity should be constantly reassessed. Low-grade CRS and ICANS are typically manageable with supportive therapy. Tocilizumab is the only approved targeted drug for CRS so far. There is evidence, that Tocilizumab and Corticosteroids do not affect efficacy of CAR T-cell therapy. However, there is a recent study suggesting inferior PFS in patients being treated with corticosteroids. Hence, corticosteroids should be considered carefully (Strati et al. Blood 2021).


Toxicity management differs between disease entities, CAR products, trials and treatment centers as there are no randomized trials for treatment strategies yet. myTcell harmonizes the grading and management according to ASTCT (Lee et al. 2019), the prescribing information, the CARTOX working group (Neelapu et al. 2017 and 2021), the SITC and EBMT recommendations (Maus et al. 2020, Yakoub-Agha et al. 2020) and the DGHO guidelines (B├╝cklein et al. 2021).


The myTcell App is not directed to any person in any jurisdiction where - by reason of that person's nationality, residence or otherwise - access to the myTcell App is prohibited. Such persons are not permitted to access the myTcell App. Each user is responsible for informing himself/herself about and complying with any self-imposed restrictions before accessing this App. 

Right to Use Content

The App, its programming, content, design and structure are subject to copyright, trademark and unfair competition laws. Copyright notices and brand designations may not be changed or removed. Any reproduction, distribution, making available for retrieval or online access of our app, the layout of the app, its contents (texts, images, programs) in whole or in part, in modified or unmodified form is only permitted with prior written consent. 


The content of this app has been compiled by FUSE GmbH in cooperation with Ludwig Maximilian University (hereinafter abbreviated as LMU). Any liability of LMU and FUSE GmbH (including negligence) for damages or consequential damages resulting from access to or use of the elements of the myTcell App (or from the impossibility of access or use) is excluded. Although the facts and figures are compiled with care, FUSE GmbH and LMU do not warrant the accuracy, completeness or correctness of any information contained herein. FUSE GmbH does not undertake to advise of any changes or partial or complete removal of the information contained herein. Corrections, additions, updates and other changes may be made without prior notice. 

FUSE GmbH has not reviewed any of the websites linked to the Site and is not responsible for the contents of any such off-site pages or any other websites linked to the App. Activating a link to off-site pages or other websites is at your own risk. 

Copyright, Property Rights

The entire content of the myTcell app is copyrighted. All rights reserved. The myTcell App logo is a registered trademark. Accessing the myTcell App, downloading or copying data from the App or any part thereof, does not grant the user any rights to the content, software, any registered trademark or any other element of the website. Any modification, reproduction or use of the App or the myTcell App logo for any public or commercial purpose is prohibited without the prior written consent of LMU. 

Legal Process and Venue

The user relationship of the myTcell App is subject to German law. The place of jurisdiction is Hamburg, Germany.